EDMONTON, Jan. 11 /CNW/ - Quest PharmaTech Inc. (TSX.V: QPT, the “Company
or Quest”) announced today that its contract research partner, Innovaderm Inc.
has received clearance from the Therapeutic Products Directorate of Health
Canada to initiate a Phase I clinical trial to investigate the topical
application of its lead photodynamic therapy (PDT) compound SL017 as a
treatment for acne and also for the removal of unwanted hair. The Principal
Investigator for the trial is Dr. Robert Bissonnette MD.
This planned study will be in addition to the Phase I clinical trial of
ACP-SL017 for photodynamic therapy of Actinic Keratosis (“AK”), which is
currently underway at the University of Alberta, with Dr. Jaggi Rao as the
Principal Investigator. The results from this trial are expected to be
available in Q1 of this year.
The acne and cosmetic hair removal trial is designed to evaluate the
histological localization of ACP-SL017 after topical application to patients
that have acne. All the necessary approvals and logistics are now in place and
the Company expects to commence enrolment very soon. It is also anticipated
that the trial will complete quickly and results will be available to support
a follow-on efficacy trial in Q2 of this year.
Is this the same thing as LHE (Light, Heat, Energy)? I got info. on this method of hair removal which uses light and heat. It’s called Radiancy. The literature claims “long-term hair removal” which I guess means it’s not permanent. Does anyone know anything about it?